SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy.

Dominique Croteau,Tomas Baka,Sara Young,Huamei He,Jordan M Chambers,Fuzhong Qin,Marcello Panagia,David R Pimentel,James A Balschi,Wilson S Colucci,Ivan Luptak

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie（2023）

引用 2|浏览16

暂无评分

摘要

Elevated myocardial [Na] contributes to mitochondrial and contractile dysfunction in DCMP. Targeting myocardial [Na] and/or NCX may be an effective strategy in DCMP and other forms of heart disease associated with elevated myocardial [Na].

查看译文

关键词

Cardiac energetics,Contractile function,Diabetic cardiomyopathy,Ertugliflozin,Myocardial intracellular sodium,Sodium-glucose co-transporter 2 (SGLT2) inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要